Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Lenvatinib, Pembrolizumab
DRUG
2 trials
Sponsors
Peking University Cancer Hospital & Institute
, Zhiyong Huang
Conditions
Mucosal Melanoma
Neoadjuvant Treatment
Unresectable Hepatocellular Carcinoma
Phase 1
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
Not yet recruiting
NCT06896396
Zhiyong Huang
Unresectable Hepatocellular Carcinoma
Start: 2025-04-01
End: 2028-02-01
Target: 60
Updated: 2025-03-26
Phase 2
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
NCT04622566
Peking University Cancer Hospital & Institute
Mucosal Melanoma, Neoadjuvant Treatment
Start: 2020-12-30
End: 2023-12-30
Target: 26
Updated: 2020-11-13
Related Papers
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma
Nature Communications
2026-05-16
NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
Journal of Clinical Oncology
2023-06-01
6 citations